← Back to Screener
MapLight Therapeutics, Inc. Common Stock (MPLT)
Price$28.01
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)97.58%
Price vs S&P 500 (4W)2.24%
VGM Score91.90
Market Capitalization$1.19B
All Metrics
Book Value / Share (Quarterly)$8.84
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.20
Price vs S&P 500 (YTD)51.31%
EPS (TTM)$-2.60
10-Day Avg Trading Volume0.34M
EPS Excl Extra (TTM)$-2.60
EPS (Annual)$-18.56
ROI (Annual)-35.16%
Cash / Share (Quarterly)$6.86
ROA (Last FY)-33.61%
EBITD / Share (TTM)$-2.73
Cash Flow / Share (Annual)$-3.15
P/B Ratio2.99x
P/B Ratio (Quarterly)2.16x
Net Income / Employee (Annual)$-1,211,700
EPS Incl Extra (Annual)$-18.56
Current Ratio (Annual)20.01x
Quick Ratio (Quarterly)21.71x
3-Month Avg Trading Volume0.25M
Revenue / Employee (TTM)$0
52-Week High$33.28
EPS Excl Extra (Annual)$-18.56
26-Week Price Return105.50%
Quick Ratio (Annual)18.80x
13-Week Price Return55.96%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)22.91x
Enterprise Value$1.14B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.93
3-Month Return Std Dev87.49%
Net Income / Employee (TTM)$-848,500
ROE (Last FY)-35.16%
EPS Basic Excl Extra (Annual)$-18.56
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.60
Revenue / Share (Annual)$0.00
Year-to-Date Return59.46%
5-Day Price Return-5.88%
EPS Normalized (Annual)$-18.56
Month-to-Date Return-4.44%
EBITD / Share (Annual)$-19.41
EPS Basic Excl Extra (TTM)$-2.60
P/B Ratio (Annual)1.74x
Book Value / Share (Annual)$10.41
Price vs S&P 500 (13W)47.70%
Beta1.57x
Revenue / Share (TTM)$0.00
52-Week Low$12.24
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-1.34est. -1.12
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.40
4.40
4.36
4.31
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MPLTMapLight Therapeutics, Inc. Common Stock | — | — | A | $28.01 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
MapLight Therapeutics is a biopharmaceutical company developing circuit-specific treatments for central nervous system disorders, targeting unmet needs in psychiatry and neuroscience. The company's differentiated approach focuses on targeting specific neural circuits rather than broad CNS pathways. Its pipeline includes multiple clinical-stage candidates, including ML-007C-MA, ML-004, ML-021, and ML-009.